All In Biotech

Drug Trial Radar · NCT06402123

A Phase 2b Study of Zagociguat in Patients With MELAS

Phase 2b Randomized, Double-blind, Placebo-controlled Crossover Study Evaluating the Efficacy and Safety of Zagociguat in Participants With MELAS (PRIZM)

Last checked: Nov 19, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

43

Actual

Start

Sep 10, 2024

Primary completion

Jun 29, 2026

Study completion Jun 29, 2026

Sponsor

Lead sponsor
Tisento TherapeuticsIndustry
Sponsor type
Industry
First posted
May 7, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Crossover
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

PRIZM is a Phase 2b randomized, double-blind, placebo-controlled, 3-treatment, 2-period, crossover study evaluating the efficacy and safety of oral zagociguat 15 and 30 mg vs. placebo when administered daily for 12 weeks in participants with genetically and phenotypically defined MELAS.

Conditions

  • Mitochondrial Encephalopathy, Lactic Acidosis and Stroke-Like Episodes (MELAS Syndrome)

Interventions

  • zagociguat 15mgDrug

    Once-daily oral tablets

  • zagociguat 30mgDrug

    Once-daily oral tablets

  • PlaceboDrug

    Once-daily oral tablets

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. • PROMIS Fatigue MELAS Short Form scores• Groton Maze Learning Test scores • International Digit Symbol Substitution Test scoresTime frame: Weeks 9 through 12 of each treatment period
  2. Incidence of Treatment-emergent Adverse Events (TEAEs)Time frame: Weeks 1 through washout for treatment period 1 and Weeks 1 through follow-up for treatment period 2

Locations

20 sites in 6 countries. Site status is shown where the registry gives one.

  • UC San Diego - Altman Clinical and Translational Research Institute

    La Jolla, California

  • Children's Hospital of Colorado

    Aurora, Colorado

  • Rare Disease Research

    Atlanta, Georgia

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Columbia University Irving Medical Center

    New York, New York

  • Mount Sinai - Ichan School of Medicine

    New York, New York

  • Akron Children's Hospital

    Akron, Ohio

  • Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania

  • Baylor College of Medicine

    Houston, Texas

  • University of Texas Medical School at Houston

    Houston, Texas

  • Neuroscience Research Australia

    Sydney, New South Wales, Australia

  • Royal Melbourne Hospital

    Melbourne, Victoria, Australia

  • Shared Health/University of Manitoba

    Winnipeg, Manitoba, Canada

  • McMaster University Medical Center

    Hamilton, Ontario, Canada

  • University Hospital Bonn

    Bonn, Germany

  • Ludwig-Maximilians-University of Munich

    Munich, Germany

  • Neurologic Institute Carlo Besta of Milan

    Milan, Italy

  • Fondazione Policlinico Universitario Agostino Gemelli

    Roma, Italy

  • Newcastle University

    Newcastle upon Tyne, United Kingdom

  • UCL Queen Square Institute of Neurology

    London, London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.